Pharmacokinetic Compartment Model
Also known as: Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli
The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses.
Key highlights
- Provides mechanistically interpretable parameters (CL, V_d, half-life) directly linking biology to drug behavior
- Enables simulation of concentration-time profiles for untested dosing regimens and patient populations
- Analytically tractable closed-form solutions exist for one- and two-compartment IV bolus scenarios
- Widely accepted by regulatory agencies (FDA, EMA) as the standard framework for NDA/MAA PK submissions
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use compartment models when you have serial plasma concentration-time data following single or multiple doses and need to estimate fundamental PK parameters (CL, V_d, half-life) for dosing optimization, bioequivalence, or drug-drug interaction assessment. The one-compartment model suits drugs with rapid distribution; the two-compartment model is required when a distinct distribution phase is visible. Assumptions include linear (first-order) kinetics, time-invariant parameters, and homogeneous mixing within each compartment. Nonlinear kinetics (e.g., Michaelis-Menten saturation) require nonlinear compartmental or empirical models instead.
Strengths & limitations
- Provides mechanistically interpretable parameters (CL, V_d, half-life) directly linking biology to drug behavior
- Enables simulation of concentration-time profiles for untested dosing regimens and patient populations
- Analytically tractable closed-form solutions exist for one- and two-compartment IV bolus scenarios
- Widely accepted by regulatory agencies (FDA, EMA) as the standard framework for NDA/MAA PK submissions
- Compartments are mathematical constructs, not anatomical structures, limiting direct physiological interpretation
- Assumes linear, time-invariant kinetics, which fails for drugs exhibiting saturable binding, autoinduction, or time-dependent PK
- Requires rich, well-timed plasma sampling; sparse data lead to poor identifiability of multi-compartment parameters
- Model selection (number of compartments) can be ambiguous when goodness-of-fit criteria give similar results
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
How do I decide between a one-compartment and a two-compartment model?
Inspect the semi-logarithmic plasma concentration-time plot: a single linear decline supports one compartment, while a biphasic curve with a distinct rapid distribution phase followed by slower terminal elimination indicates two compartments. Formal selection uses the Akaike Information Criterion (AIC) or likelihood ratio test, combined with visual inspection of residuals and the precision of parameter estimates.
What is the clinical significance of the volume of distribution?
Volume of distribution (V_d) quantifies how extensively a drug distributes beyond plasma into tissues. A large V_d (greater than total body water, roughly 42 L in a 70 kg adult) indicates extensive tissue binding or lipophilicity, which prolongs half-life and means plasma drug levels underrepresent total body load — important when assessing overdose or dialyzability.
Can compartment models handle oral dosing?
Yes. For extravascular routes, a first-order absorption compartment is prepended to the central compartment, adding an absorption rate constant k_a to the model. The plasma concentration then follows a difference of exponentials: C(t) = [F·D·k_a / (V·(k_a − k_el))] · (e^(−k_el·t) − e^(−k_a·t)), where F is bioavailability. Flip-flop kinetics must be checked when k_el exceeds k_a.
Sources
- 1.Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker.ISBN 978-0-8247-1042-2
You have read it. What now?
Cite this page
ScholarGate. (2026, June 2). Pharmacokinetic Compartment Model. ScholarGate. https://scholargate.app/pharmacometrics/pharmacokinetic-compartment-model